Single-arm trials for domestic oncology drug approvals in China

Single-arm trials for domestic oncology drug approvals in China

Bibliographic Details
Main Authors:	Hong Zhang, Sen Liu, Chenghao Ge, Xiaozhen Liu, Yang Liu, Chen Yin, Yi Li, Jing An, Zhongtian Yan, Xiaoyuan Chen
Format:	Article
Language:	English
Published:	China Anti-Cancer Association 2023-11-01
Series:	Cancer Biology & Medicine
Online Access:	https://www.cancerbiomed.org/content/20/11/799

Similar Items

Analysis of patient-reported outcomes in the approval of novel oncology drugs in the United States, 2017–2022Research in context
by: Chenghao Ge, et al.
Published: (2023-05-01)

International oncology drug approvals for multiregional or single-country clinical trials: A systematic review
by: Min Zhang, et al.
Published: (2022-12-01)

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
by: Valentina Tateo, et al.
Published: (2023-04-01)

Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years
by: Rosa Falcone, et al.
Published: (2022-02-01)

Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006–2021: a cross-sectional study
by: Yi Chen, et al.
Published: (2023-06-01)

Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials
by: Lauren A. Marcath, et al.
Published: (2018-11-01)

The accelerated approval process in oncology : an examination of the conversion rate of approved therapies to full approval
by: Kim, Jean Jinsun
Published: (2007)

Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022Research in context
by: Xingxian Luo, et al.
Published: (2023-09-01)

Can a propensity score matching method be applied to assessing efficacy from single‐arm proof‐of‐concept trials in oncology?
by: Shu‐Wen Teng, et al.
Published: (2023-09-01)

Clinical evaluation of the first domestically produced generic isosulfan blue injection in sentinel lymph node biopsy for early breast cancer in China: a multicenter, single-arm, open validation trial (CSBrS-024)
by: Fengjiang Qu, et al.
Published: (2022-07-01)

Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021
by: Catherine Lau, et al.
Published: (2022-10-01)

Approval requirements for domestic gas refrigerators /
by: Australian Gas Association
Published: (1977)

Were economic evaluations well reported for the newly listed oncology drugs in China’s national reimbursement drug list
by: Liu Liu, et al.
Published: (2022-12-01)

The Singapore Armed Forces and Domestic Security
by: Lee, Terence
Published: (2016)

Review time of oncology drugs and its underlying factors: an exploration in China
by: Xingyue Zhu, et al.
Published: (2023-11-01)

Use of suboptimal control arms in randomized clinical trials of investigational cancer drugs in China, 2016–2021: An observational study
by: Yichen Zhang, et al.
Published: (2023-12-01)

Approval requirements for domestic space heating appliances /
by: Australian Gas Association, et al.
Published: (1977)

Comparative oncology using domesticated dogs and their microbiome
by: Tasha M. Santiago-Rodriguez
Published: (2024-03-01)

Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects
by: Roohi Mohi-ud-din, et al.
Published: (2023-09-01)

Theoretical Prediction of Dual-Potency Anti-Tumor Agents: Combination of Oxoplatin with Other FDA-Approved Oncology Drugs
by: José Pedro Cerón-Carrasco
Published: (2020-07-01)

Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial
by: Jia Wei, et al.
Published: (2023-08-01)

Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
by: Amelia D. Dahlén, et al.
Published: (2022-01-01)

Anticancer drug development guide : preclinical screening, clinical trials, and approval /
by: Teicher, Beverly A., 1952-, et al.
Published: (2004)

Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
by: Shigeto Nishikawa, et al.
Published: (2023-01-01)

High-Throughput Screening of FDA-Approved Drug Library Reveals Ixazomib Is a Broad-Spectrum Antiviral Agent against Arboviruses
by: Cuiling Ding, et al.
Published: (2022-06-01)

Evaluating a Remotely Delivered Cardio-Oncology Rehabilitation Intervention for Patients With Breast Cancer (REMOTE-COR-B): Protocol for a Single-Arm Feasibility Trial
by: Camille E Short, et al.
Published: (2024-04-01)

Efficacy and safety of ciprofol for agitation and delirium in the ICU: A multicenter, single-blind, 3-arm parallel randomized controlled trial study protocol
by: Guo Liang Liu, et al.
Published: (2023-01-01)

Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
by: Min Yan, et al.
Published: (2023-10-01)

FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment
by: Cheryl Ho, et al.
Published: (2022-01-01)

Drug Discovery in Oncology
by: Carlos García-Echeverría
Published: (2004-09-01)

The reimbursement decision speed for oncology new drugs in China and its determinant factors
by: Xingyue Zhu, et al.
Published: (2023-10-01)

Translatability of in vitro potency to clinical efficacious exposure: A retrospective analysis of FDA‐approved targeted small molecule oncology drugs
by: Naoki Kotani, et al.
Published: (2023-08-01)

Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs
by: Ha Yeong Choi, et al.
Published: (2023-09-01)

Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials
by: Simona Duranti, et al.
Published: (2021-10-01)

From Life in the Sea to the Clinic: The Marine Drugs Approved and under Clinical Trial
by: Emiliano Cappello, et al.
Published: (2021-12-01)

Synthesis and clinical application of new drugs approved by FDA in 2022
by: Jing-Yi Zhang, et al.
Published: (2023-09-01)

Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments
by: Katherine Appiah, et al.
Published: (2024-01-01)

Simulation studies to quantify the impact of competing risk events in a hypothetical scenario of falling antimalarial drug efficacy in single-armed and comparative drug trials
by: Dahal, P, et al.
Published: (2018)

Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trialResearch in context
by: Yan Liang, et al.
Published: (2024-05-01)

Clinical trials in oncology /
by: 214712 Green, Stephanie, et al.
Published: (2003)